The targeted protein degradation enabling technologies market



Targeted protein degradation has emerged as a revolutionary pharmacological concept that presents both viable

Press Release

Report Keywords- Targeted Protein, Degradation Market, Roots Analysis, Report, Analysis


Targeted protein degradation has emerged as a revolutionary pharmacological concept that presents both viable and versatile drug development opportunities and is anticipated to introduce a new paradigm in modern healthcare




Roots Analysis has announced the addition of “Targeted Protein Degradation Market, 2021-2030” report to its list of offerings.


Small-molecule-induced protein degradation has been demonstrated to possess the potential to drug a broader range of proteinaceous biological targets. It involves the selective recruitment of the body’s inherent protein degradation pathways, to eliminate disease causing / associated proteins, using bifunctional small molecule drugs. Presently, the most popular and promising class of interventions in this field of research, is proteolysis targeting chimeras (PROTACs); these can simultaneously bind a target protein and an E3-ubiquitin ligase, and thereby, facilitate the selective ubiquitination and eventual proteasome-mediated degradation of the target protein. The most interesting feature of this mechanism of drug action is the fact that PROTACs and other targeted protein degraders can eliminate protein targets regardless of their function.


To order this 330+ page report, which features 115+ figures and 180+ tables, please visit –



Key Market Insights 


Presently, more than 150 targeted protein degradation-based therapeutics are currently under development

Around 75% of the aforementioned candidates are in the preclinical and discovery stages, followed by those that are being evaluated in clinical trials (25%). The these degrader molecules are PROTAC (26), followed by DUB inhibitors (15%), protein homeostatic modulators (14%) and SERDs/SARDs (13%).



Around 80 companies claim to be engaged in the development of targeted protein degradation-based therapeutics

Post 2010, there has been a notable surge in the number of companies developing targeted protein degraders. Majority of the firms engaged in this field (57%) are based in North America, followed by Europe (27%) and the Asia Pacific (16%).


Over 80 registered clinical trials are presently assessing targeted protein degradation-based therapeutics, worldwide

It is worth mentioning that most of the clinical research in this direction is being conducted in Europe (60%), followed by North America and the Asia Pacific. However, more than 40% of the total number of patients enrolled in such trials are in North America.




Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[email protected]

Facebook –

LinkedIn –

Twitter –